BREAKING
COMPASS Pathways plc (CMPS) Reports Q4 Earnings 10 minutes ago Core & Main, Inc. (CNM) Misses Q4 EPS Estimates by 32.3% 14 minutes ago Concentrix Corporation (CNXC) Misses Q1 EPS Estimates 20 minutes ago Sanara MedTech Inc. (SMTI) Misses Q4 EPS Estimates by 215.9% 26 minutes ago Achieve Life Sciences, Inc. (ACHV) Reports Wider Q4 Loss Than Expected 37 minutes ago Smithfield Foods, Inc. (SFD) Reports Q4 Earnings 50 minutes ago Talphera Inc (TLPH) Reports Q4 Earnings 22 hours ago NVIDIA (NVDA) eyes China AI chip re-entry as export licensing shifts to case-by-case review 4 days ago Qualcomm (QCOM) authorizes $20B stock repurchase program, raises quarterly dividend to $0.92 4 days ago UP Fintech Holding Limited Reports Strong 2025 Results 4 days ago COMPASS Pathways plc (CMPS) Reports Q4 Earnings 10 minutes ago Core & Main, Inc. (CNM) Misses Q4 EPS Estimates by 32.3% 14 minutes ago Concentrix Corporation (CNXC) Misses Q1 EPS Estimates 20 minutes ago Sanara MedTech Inc. (SMTI) Misses Q4 EPS Estimates by 215.9% 26 minutes ago Achieve Life Sciences, Inc. (ACHV) Reports Wider Q4 Loss Than Expected 37 minutes ago Smithfield Foods, Inc. (SFD) Reports Q4 Earnings 50 minutes ago Talphera Inc (TLPH) Reports Q4 Earnings 22 hours ago NVIDIA (NVDA) eyes China AI chip re-entry as export licensing shifts to case-by-case review 4 days ago Qualcomm (QCOM) authorizes $20B stock repurchase program, raises quarterly dividend to $0.92 4 days ago UP Fintech Holding Limited Reports Strong 2025 Results 4 days ago
ADVERTISEMENT
Breaking News

Sanara MedTech Inc. (SMTI) Misses Q4 EPS Estimates by 215.9%

Sanara MedTech Inc.

March 24, 2026 2 min read

Sanara MedTech Inc.

SMTISMTI|EPS -$0.13 vs $0.11 est (-215.9%)|Rev $27.5M|Net Loss $1.1M

Sanara MedTech Inc. reported a surprise loss for the fourth quarter of 2025, with GAAP earnings coming in at -$0.13 per share against analyst expectations of a $0.11 profit. The medical technology company, which markets surgical and wound care products to healthcare providers, missed the consensus estimate by 215.9%. The bottom line showed a net loss of $1.1M for the period.

Revenue totaled $27.5M for the quarter, representing 5.0% year-over-year growth. The company’s soft tissue repair products segment continued to drive performance, generating $24.7M in revenue with a 5.0% year-over-year increase. These products remain the cornerstone of Sanara’s portfolio as it serves physicians, hospitals, clinics, and post-acute care settings.

For the full year ahead, management set revenue guidance at $116.0M to $121.0M. The forecast comes as the company navigates a competitive landscape in the wound care and surgical products market, balancing growth initiatives against profitability challenges that emerged in the latest quarter.

A detailed analysis of Sanara MedTech Inc.’s quarter follows shortly on AlphaStreet.

This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.

ADVERTISEMENT